Gilder Gagnon Howe & CO LLC Sarepta Therapeutics, Inc. Transaction History

Gilder Gagnon Howe & CO LLC

$7.87 Billion
Q3 2024

A detailed history of Gilder Gagnon Howe & CO LLC transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Gilder Gagnon Howe & CO LLC holds 9,687 shares of SRPT stock, worth $1.15 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

9,687

Previous 12,502 22.52%

Holding current value

$1.15 Million

Previous $1.98 Million 38.78%

% of portfolio

0.02%

Previous 0.03%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$124.33 - $156.75 $349,988 - $441,251	-2,815 Reduced 22.52%	9,687 $1.21 Million
Q2 2024 Aug 14, 2024	SELL	$113.33 - $163.85 $531,744 - $768,784	-4,692 Reduced 27.29%	12,502 $1.98 Million
Q1 2024 May 15, 2024	SELL	$93.7 - $141.53 $39,166 - $59,159	-418 Reduced 2.37%	17,194 $2.23 Million
Q4 2023 Feb 14, 2024	BUY	$67.31 - $124.76 $67,444 - $125,009	1,002 Added 6.03%	17,612 $1.7 Million
Q3 2023 Nov 14, 2023	BUY	$102.5 - $123.59 $25,625 - $30,897	250 Added 1.53%	16,610 $2.01 Million
Q2 2023 Aug 14, 2023	SELL	$106.4 - $157.19 $44,049 - $65,076	-414 Reduced 2.47%	16,360 $1.87 Million
Q1 2023 May 15, 2023	SELL	$117.53 - $155.99 $27,854 - $36,969	-237 Reduced 1.39%	16,774 $2.31 Million
Q4 2022 Feb 14, 2023	SELL	$100.86 - $132.13 $1,613 - $2,114	-16 Reduced 0.09%	17,011 $2.2 Million
Q3 2022 Nov 14, 2022	BUY	$75.71 - $119.24 $721,289 - $1.14 Million	9,527 Added 127.03%	17,027 $1.88 Million
Q2 2022 Aug 15, 2022	SELL	$62.69 - $88.44 $250 - $353	-4 Reduced 0.05%	7,500 $562,000
Q1 2022 May 16, 2022	SELL	$63.15 - $90.42 $19,197 - $27,487	-304 Reduced 3.89%	7,504 $586,000
Q4 2021 Feb 14, 2022	SELL	$77.28 - $99.42 $2,550 - $3,280	-33 Reduced 0.42%	7,808 $703,000
Q3 2021 Nov 15, 2021	SELL	$65.97 - $92.48 $13,589 - $19,050	-206 Reduced 2.56%	7,841 $725,000
Q2 2021 Aug 16, 2021	SELL	$69.38 - $86.75 $138 - $173	-2 Reduced 0.02%	8,047 $626,000
Q1 2021 May 17, 2021	SELL	$72.25 - $168.95 $46.2 Million - $108 Million	-639,306 Reduced 98.76%	8,049 $600,000
Q4 2020 Feb 16, 2021	SELL	$125.56 - $178.74 $27.2 Million - $38.8 Million	-216,893 Reduced 25.1%	647,355 $110 Million
Q3 2020 Nov 16, 2020	SELL	$127.12 - $172.34 $4.5 Million - $6.1 Million	-35,423 Reduced 3.94%	864,248 $121 Million
Q2 2020 Aug 14, 2020	SELL	$93.0 - $171.7 $2.66 Million - $4.91 Million	-28,611 Reduced 3.08%	899,671 $144 Million
Q1 2020 May 15, 2020	SELL	$82.38 - $131.64 $1.28 Million - $2.04 Million	-15,529 Reduced 1.65%	928,282 $90.8 Million
Q4 2019 Feb 14, 2020	SELL	$76.53 - $135.58 $507,393 - $898,895	-6,630 Reduced 0.7%	943,811 $122 Million
Q3 2019 Nov 14, 2019	SELL	$72.81 - $156.91 $3.03 Million - $6.52 Million	-41,566 Reduced 4.19%	950,441 $71.6 Million
Q2 2019 Aug 13, 2019	SELL	$112.21 - $151.95 $40,844 - $55,309	-364 Reduced 0.04%	992,007 $151 Million
Q1 2019 May 17, 2019	BUY	$106.67 - $151.68 $1.78 Million - $2.53 Million	16,666 Added 1.71%	992,371 $118 Million
Q4 2018 Feb 14, 2019	SELL	$97.32 - $148.76 $378,574 - $578,676	-3,890 Reduced 0.4%	975,705 $106 Million
Q3 2018 Oct 30, 2018	SELL	$115.31 - $161.51 $724,031 - $1.01 Million	-6,279 Reduced 0.64%	979,595 $158 Million
Q2 2018 Jul 31, 2018	SELL	$71.74 - $153.69 $898,902 - $1.93 Million	-12,530 Reduced 1.26%	985,874 $130 Million
Q1 2018 Apr 30, 2018	BUY	$54.02 - $82.27 $6.78 Million - $10.3 Million	125,580 Added 14.39%	998,404 $74 Million
Q4 2017 Jan 31, 2018	BUY	$47.64 - $56.75 $16.1 Million - $19.2 Million	338,737 Added 63.42%	872,824 $48.6 Million
Q3 2017 Nov 06, 2017	BUY	$35.73 - $47.15 $19.1 Million - $25.2 Million	534,087	534,087 $24.2 Million

Others Institutions Holding SRPT

# of Institutions

529

Shares Held

84.2M

Call Options Held

2.06M

Put Options Held

1.52M

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.4B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.

Account

Gilder Gagnon Howe & CO LLC Sarepta Therapeutics, Inc. Transaction History